Skip to main content

Table 1 Absence of toxicity of RSG and QC in nasal mucosa explants

From: CCL2 and CCL5 driven attraction of CD172a+ monocytic cells during an equine herpesvirus type 1 (EHV-1) infection in equine nasal mucosa and the impact of two migration inhibitors, rosiglitazone (RSG) and quinacrine (QC)

Localization (nasal mucosa) Products Percentage (%) of TUNEL-positive cells treated at… μM at 72 hpi
0 (mock) 1 3 10 30
Epithelium RSG 0.3 ± 0.2 0.4 ± 0.3 0.7 ± 0.6 0.6 ± 0.5 1.1 ± 0.6
QC 0.4 ± 0.1 0.7 ± 0.3 1.2 ± 0.6 1.4 ± 0.6 1.6 ± 0.7
Lamina propria RSG 0.5 ± 0.6 1.4 ± 0.8 3.0 ± 0.7 2.8 ± 1.9 4.0 ± 1.1
QC 0.6 ± 0.2 1.2 ± 0.7 2.7 ± 0.9 3.2 ± 0.7 4.7 ± 1.6
  1. Viability of nasal mucosa explants treated with RSG or QC at different concentrations was determined in the TUNEL assay at 72 hpi. Values are given as mean ± SD of 3 different experiments.